Share on StockTwits

Dechra Pharmaceuticals plc (LON:DPH)‘s stock had its “buy” rating reaffirmed by investment analysts at Panmure Gordon in a note issued to investors on Thursday. They currently have a GBX 850 ($14.11) price target on the stock. Panmure Gordon’s price target suggests a potential upside of 16.84% from the stock’s previous close.

Shares of Dechra Pharmaceuticals plc (LON:DPH) opened at 731.00 on Thursday. Dechra Pharmaceuticals plc has a 52 week low of GBX 655.00 and a 52 week high of GBX 755.00. The stock’s 50-day moving average is GBX 708.8 and its 200-day moving average is GBX 699.6. The company’s market cap is £637.5 million.

A number of other analysts have also recently weighed in on DPH. Analysts at Oriel Securities Ltd reiterated a “hold” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday, July 8th. They now have a GBX 690 ($11.45) price target on the stock. Separately, analysts at N+1 Singer reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday, July 8th. They now have a GBX 760 ($12.61) price target on the stock. Finally, analysts at FinnCap reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday, July 8th. They now have a GBX 800 ($13.28) price target on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of GBX 781 ($12.96).

Dechra Pharmaceuticals PLC is a United Kingdom-based veterinary pharmaceutical company. The Company is engaged in developing, manufacturing, distributing, selling and marketing of animal products to the veterinary industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.